Development and validation of an HPLC method for the determination of fluorouracil in polymeric nanoparticles

Brazilian Journal of Pharmaceutical Sciences

Volumn 49, Issue 1, 2013, Pages 117-126

  de Mattos, Ana Cristina ^a   Khalil, Najeh Maissar ^a   Mainardes, Rubiana Mara ^a  

^a UNIVERSIDADE ESTADUAL DO CENTRO OESTE   (Brazil)

Author keywords

Fluorouracil determination; High performance liquid chromatography quantitative analysis method validation; Nanoparticles

Indexed keywords

ACETONITRILE; FLUOROURACIL; MACROGOL; NANOPARTICLE; POLYLACTIC ACID; WATER;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG FORMULATION; ENCAPSULATION; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; QUANTITATIVE ANALYSIS; TEMPERATURE; VALIDATION PROCESS;

EID: 84876911365     PISSN: 19848250     EISSN: 21759790     Source Type: Journal    
DOI: 10.1590/S1984-82502013000100013     Document Type: Article

References (32)

1. AKAGI, T.; KANEKO, T.; KIDA, T.; AKASHI, M. Preparation and characterization of biodegradable nanoparticles based on poly(g-glutamic acid) with l-phenylalanine as a protein carrier. J. Control. Release, v.108, n.2-3, p.226-236, 2005.
2. ALEXIS F.; PRIDGEN E.;MOLNAR, L.K.;FAROKHZAD, O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm., v.5, n.4, p.505-515, 2008.
3. ANDERSON, D.; KERR, D.J.; BLESING, C.; SEYMOUR, L.W. Simultaneous gas chromatographic-mass spectrophotometric determination of a-fluoro-P-alanine and 5-fluorouracil in plasma. J. Chromatogr. B, v.688, n.1, p.87-93, 1997.
4. ARBÓS, P.; CAMPANERO, M.A.; IRACHE, J.M. RP-LC determination of 5-fluorouridine in nanoparticulate formulations. J. Pharm. Biomed. Anal., v.28, n.5, p.857-866, 2002.
5. BADEA, I.; MOJA, D.; TUDOSE, A.; STOICESCU, D. Determination of the 5-fluorouraciland N1(2?-furanidyl)uracil in the presence of tegafur by zero-crossing first derivative spectrometry. J. Pharm. Biomed. Anal., v.30, n.4, p.1371-1378, 2002.
6. BOZKIR, A.; SAKA, O.M. Formulation and investigation of 5-FU nanoparticles with factorial design-based studies. Farmaco, v.60, n.10, p.840-846, 2005.
7. CASALE, F., CANAPARO, R; SERPE, L.; MUNTONI, E.; PEPA, C. D; COSTA, M.; MAIRONE, L.; ZARA, G.P.; FORNARI, G.; EANDI, M. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol. Res., v.50, n.2, p.173-179, 2004.
8. DAS NEVES, J.; SARMENTO, B.; AMIJI, M.M.; BAHIA, M.F. Development and validation of a rapid reversed-phase HPLC method for the determination of the non-nucleoside reverse transcriptase inhibitor dapivirine from polymeric nanoparticles, J. Pharm. Biomed. Anal., v.52, n.2, p.167-172, 2010.
9. ESCORIAZA, J.; ALDAZ, A.; CALVO, E.;GIRÁLDEZ, J. Simple and sensitive determination of 5-fluorouracil in plasma by high-performance liquid chromatography. Application to clinical pharmacokinetic studies. J. Chromatogr. B, v.736, n.1-2, p.97-102, 1999.
10. GAMELIN, E., BOISDRON-CELLE, M. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer-status of the art. Crit. Rev. Oncol. Hemat., v.30, n.1, p.71-79, 1999.
11. GAMELIN, E.; BOISDRON-CELLE, M.; GUÉRIN-MEYER, V.; DELVA, R.; LORTHOLARY, A.; GENEVIEVE, F. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J. Clin. Oncol., v.17, n.4, p.1105-1110, 1999.
12. GREM, J.L. Fluorinated pyrimidines. In: CHABNER, B.A.; COLLINS, J.M. (Eds.) Cancer chemotherapy: principles and practice. Philadelphia: J.B. Lippincott, 1990. p.180-224.
13. INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. ICH HARMONISED TRIPARTITE GUIDELINE: Validation of Analytical procedures: text and methodology Q2(R1), 2005, p. 1-13.
14. LABHASETWAR, V.; PRABHA, S. Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. Mol. Pharm., v.1, n.3, p.211-219, 2004.
15. LAI, L.F.; GUO, H.X. Preparation of new 5-fluorouracil-loaded zein nanoparticles for liver targeting. Int. J. Pharm., v.404, n.1-2, p.317-323, 2011.
16. LI, P.; WANG, Y.; PENG, Z.; SHE, F.; KONG, L. Development of chitosan nanoparticles as drug delivery systems for 5-fluorouracil and leucovorin blends. Carbohyd. Polym., v.85, n.3, p.698-704, 2011.
17. LICEA-PEREZ, H.; WANG, S.; BOWEN, C. Development of a sensitive and selective LC MS/MS method for the determination of α-fluoro-β-alanine, 5-fluorouracil and capecitabine in human plasma. J. Chromatogr. B, v.877, n.11-12, p.1040-1046, 2009.
18. LIU, L.; JIN, P.; CHENG, M.; ZHANG, G.;ZHANG, F. 5-Fluorouracil-loaded self assembled ph-sensitive nanoparticles as novel drug carrier for treatment of malignant tumors. Chinese J. Chem. Eng., v.14, n.3, p.377-382, 2006.
19. LIU, K.; ZHONG, D.; ZOU, H.; CHEN, X. Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal., v.52, n.4, p.550-556, 2010.
20. MOGHIMI, S.M.; HUNTER, A.C.; MURRAY, J.C. Long-circulating and target specific nanoparticles: theory to practice. Pharmacol. Rev., v.53, p.283-318, 2001.
21. PANYAM, J.; LABHASETWAR, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliver. Rev., v.55, n.3, p.329-347, 2003.
22. PETERS, G.J.; VAN GROENINGEN, C.J. Clinical relevance of biochemical modulation of 5-fluorouracil. Ann. Oncol., v.2, n.7, p.469-480, 1991.
23. PINEDO, H.M.; PETERS, G.F. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol., v.6, n.10, p.1653-1664, 1988.
24. PISANO, R.; BREDA, M.; GRASSI, S.; JAMES, C.A. Hydrophilic interaction liquid chromatography-APCI-mass spectrometry determination of 5-fluorouracil in plasma and tissues. J. Pharm. Biomed. Anal., v.38, n.4, p.738-745, 2005.
25. REJINOLD, N.S.; CHENNAZHI, K.P.; NAIR, S.V.; TAMURA, H.; JAYAKUMAR, R. Biodegradable and thermo-sensitive chitosan-g-poly(N-vinylcaprolactam) nanoparticles as 5-fluorouracil Carrier. Carbohyd. Polym., v.83, n.2, p.776-786, 2011a.
26. REJINOLD, N.S.; MUTHUNARAYANAN, M.; CHENNAZHI, K.P.; NAIR, S.V.; JAYAKUMAR, R. 5-Fluorouracil loaded fibrinogen nanoparticles for cancer drug delivery application. Int. J. Biol. Macromol., v.48, n.1, p.98-105, 2011b.
27. TANAKA, F.; FUKUSE, T.; WADA, H.; FUKUSHIMA, M. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents. Curr. Pharm. Biotech., v.1, n.2, p.137-164, 2000.
28. UNITED STATES PHARMACOPEIA. USP 34: The National formulary: NF 29: by authority of the United States Pharmacopeia Convention prepared by the council of experts and its expert committees. 29. ed. Rockville: United States Pharmacopeia Convention, 2010. v.2, p.2874-2875.
29. ZHANG, Y.; LI, J.; LANG, M.; TANG, X.; LI, L.; SHEN, X. Folate-functionalized nanoparticles for controlled 5-Fluorouracil delivery. J. Colloid Interf. Sci., v.354, n.1, p.202-209, 2011.
30. ZHENG, Y.; YANG, W.; WANG, C.; HU, J.; FU, S.; DONG, L.; WU, L.; SHEN, X. Nanoparticles based on the complex of chitosan and polyaspartic acid sodium salt: Preparation, characterization and the use for 5-fluorouracil delivery. Eur. J. Pharm. Biopharm., v.67, n.3, p.621-631, 2007.
31. ZHU, L.; MA, J.; JIA, N.; ZHAO, Y.; SHEN, H. Chitosan-coated magnetic nanoparticles as carriers of 5-Fluorouracil: Preparation, characterization and cytotoxicity studies. Coll. Surf. B, v.68, n.1, p.1-6, 2009.
32. ZAMBAUX, M.F.; BONNEAUX, F.; GREF, R.; MAINCENT, P.; DELLACHERIE, E.; ALONSO, M.J.; LABRUDE, P.; VIGNERON, C. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J. Control. Release, v.50, n.1-3, p.31-40, 1998.